Circulating levels and ex vivo production of β-chemokines, interferon γ, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: The effect of protease inhibitor therapy

Andrea De Luca, Maria Letizia Giancola, Antonella Cingolani, Adriana Ammassari, Rita Murri, Andrea Antinori

Research output: Contribution to journalArticle

Abstract

Cytokines and β-chemokines play an important role in the complex interaction between HIV-1 and the immune system. We studied platelet-free plasma (PFP) levels and ex vivo production of cytokines and β-chemokines at different HIV disease stages and the influence of potent protease inhibitor therapy on their production in late-stage patients. Mitogen-induced production of MIP-1α, MIP-1β, and RANTES by PBMCs was higher in HIV- infected patients than in HIV-seronegative controls. Patients with late-stage HIV infection (CD4+ cells + cells >150/μl). Pretreatment RANTES production correlated negatively with CD4+ and CD8+ cell counts; also, MIP-1α production was inversely correlated with CD4+ cell counts. Among patients with a CD4+ cell count + cell counts after protease inhibitor therapy. The production of MIP-1α, MIP-1β, RANTES, and IFN-γ was markedly reduced at 8 weeks and partially restored at 24 weeks after beginning protease inhibitor therapy. PFP levels of RANTES showed a concurrent decrease. Patients with more advanced HIV infection show a higher production of inflammatory cytokines, which is reduced by protease inhibitor therapy. Residual late-stage IL-2 producers may represent a subset of patients with a higher potential for immunologic reconstitution.

Original languageEnglish
Pages (from-to)835-843
Number of pages9
JournalAIDS Research and Human Retroviruses
Volume16
Issue number9
DOIs
Publication statusPublished - Jun 10 2000

ASJC Scopus subject areas

  • Immunology
  • Virology

Fingerprint Dive into the research topics of 'Circulating levels and ex vivo production of β-chemokines, interferon γ, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: The effect of protease inhibitor therapy'. Together they form a unique fingerprint.

  • Cite this